ARTRADOL - instructions for use, dose, side effects, contraindications

Chondroitin sodium sulfate	250.0 mg	500.0 mg
Excipients:
Croscarmellose sodium	20.0 mg	20.0 mg
Povidone-K25	5.0 mg	5.0 mg
Microcrystalline cellulose	140.0 mg	60.0 mg
Magnesium stearate	5.0 mg	5.0 mg

Hard gelatin capsules № 0

Capsule composition: Capsule case: titanium dioxide - 2.0%, gelatin - up to 100%.

Capsule cap: Azorubin dye 0.0016%, quinoline yellow dye 1.1496%, blue patented dye 0.1672%, black diamond dye 0.0958%, titanium dioxide 1.3333%, gelatin 100% %.

Capsules hard gelatinous № 00

Capsule body composition: Capsule case: dye azorubin - 0.5680%, dye diamond black - 0.0019%, titanium dioxide - 1.3333%, dye sunset yellow -0.1861%, gelatin - up to 100%.

Capsule cover: azorubin dye - 0.5680%, diamond black dye - 0.0019%, titanium dioxide - 1.3333%, dye sunset yellow - 0.1861%, gelatin - up to 100%.

Description:

Capsules 250 mg: capsule number 0. The capsule body is white, the lid is dark green, opaque.

Capsules 500 mg: capsule number 00. The capsule body is bright red, the lid is bright red, opaque.

The contents of the capsules are a mixture of powder and granules with crystalline inclusions, white or white with a yellowish hue of color. Granules of irregular shape, different sizes, it is allowed to seal the contents of the capsule according to the shape of the capsule, disintegrating when pressed with a glass rod.

Pharmacotherapeutic group:Regeneration of tissue stimulant

ATX: & nbsp

M.01.A.X.25 Chondroitin sulfate

Pharmacodynamics:It affects the metabolic processes in hyaline and fibrous cartilage, reduces degenerative changes in the cartilaginous tissue of the joints, stimulates the biosynthesis of glycosaminoglycans. Slows the resorption of bone tissue and reduces calcium loss, accelerates the recovery of bone tissue. When treated with ARTRADOL®, soreness decreases and the mobility of affected joints improves. The therapeutic effect persists for a long time after the end of the course of treatment.

Pharmacokinetics:

More than 70% of chondroitin sulfate is absorbed in the digestive tract.

Bioavailability of the drug is 13%.With a single admission of the medial therapeutic dose, the maximum concentration in the plasma is noted after 3 to 4 hours, in the synovial fluid after 4-5 hours. The drug absorbed in the gastrointestinal tract accumulates in the synovial fluid. It is excreted by the kidneys.

Indications:

Degenerative diseases of the joints and spine: primary arthrosis, intervertebral osteochondrosis.

Contraindications:

Hypersensitivity to the components of the drug.

Children under 15 years of age (due to lack of accurate data).

Carefully:Patients with bleeding, as well as patients with a tendency to bleeding, thrombophlebitis.

Pregnancy and lactation:

The use of the drug ARTRADOL® during pregnancy and during breastfeeding is contraindicated.

Dosing and Administration:

Inside, washing down with water. Adults and adolescents with 15 years of age appoint 1 g per day - 2 capsules 250 mg or 1 capsule 500 mg 2 times a day. The recommended duration of the initial course of treatment is 6 months, the period of the drug after its withdrawal is 3-5 months depending on the location and stage of the disease, the duration of repeated courses of treatment is established by the doctor.

Side effects:

From the digestive system: nausea, vomiting.

Allergic reactions: Allergic reactions (urticaria, erythema, skin itching).

Overdose:

In rare cases, symptoms of an overdose on the part of the gastrointestinal tract are possible: nausea, vomiting, diarrhea; with prolonged intake of excessively high doses (over 3 g / day), hemorrhagic eruptions are possible. Treatment is symptomatic.

Interaction:

With the simultaneous use of the drug ARTRADOL® with other drugs, it is possible to increase the effect of indirect anticoagulants, antiplatelet agents, fibrinolytic agents.

Effect on the ability to drive transp. cf. and fur:

The drug ARTRADOL® does not affect the ability to drive vehicles and to engage in potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Form release / dosage:

Capsules 250 mg and 500 mg.

Packaging:

For 5, 6, 10 capsules in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

For 10, 20, 30, 50, 60 or 120 capsules in a polymer can for medicines,sealed with a high-pressure polyethylene lid with a first opening control or a low-pressure polyethylene lid with a first opening control, or a "push-turn" polypropylene lid.

One bank or 1, 2, 3, 4, 5, 6, or 12 contour mesh packages together with the instruction for use are placed in a cardboard package (bundle).

Storage conditions:

At a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years. Do not use after expiry date.

Terms of leave from pharmacies:Without recipe

Registration number:LP-004234

Date of registration:06.04.2017

Expiration Date:06.04.2022

The owner of the registration certificate:TRIVIUM-XXI, LLC TRIVIUM-XXI, LLC Russia

Manufacturer: & nbsp

OZONE, LLC Russia

Information update date: & nbsp17.05.2017

Illustrated instructions

Instructions

ARTRADOL® (Artradol)